20919-36-2

Basic information

• Product Name: N-BENZYL-2-HYDROXY-BENZAMIDE
• Synonyms: BenzaMide,2-hydroxy-N-(phenylMethyl)-
• CAS NO: 20919-36-2
• Molecular Formula: C₁₄H₁₃NO₂
• Molecular Weight: 227.26
• Mol File: 20919-36-2.mol
• Article Data: 23

Chemical Properties

• Melting Point: 136 °C
• Boiling Point: 450.7°Cat760mmHg
• Flash Point: 226.4°C
• Appearance: /
• Density: 1.202g/cm³
• Vapor Pressure: 9.7E-09mmHg at 25°C
• Refractive Index: 1.618
• PKA: 8.51±0.30(Predicted)
• CAS DataBase Reference: N-BENZYL-2-HYDROXY-BENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-BENZYL-2-HYDROXY-BENZAMIDE(20919-36-2)
• EPA Substance Registry System: N-BENZYL-2-HYDROXY-BENZAMIDE(20919-36-2)

Safety Data

• Hazardous Substances Data: 20919-36-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C14H13NO2/c16-13-9-5-4-8-12(13)14(17)15-10-11-6-2-1-3-7-11/h1-9,16H,10H2,(H,15,17)

Upstream product

• 100-46-9 benzylamine 
• 69-72-7 salicylic acid 
• 65-45-2 salicylamide 
• 100-51-6 benzyl alcohol 
• 609-65-4 o-chlorobenzoyl chloride 
• 73178-23-1 N-benzyl-2-iodobenzamide 
• 7506-50-5 N-(o-chlorobenzoyl)benzylamine 
• 609-67-6 2-Iodobenzoyl chloride 
• 88-67-5 2-Iodobenzoic acid 
• 183198-63-2 N-benzyl-2-methoxylbenzamide 
• 2037-99-2 3-benzyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione 
• 61141-14-8 anionic phenyl salicylate 
• 1441-87-8 salicyloyl chloride 
• 119-36-8 methyl salicylate 

Downstream Products

• 143000-11-7 3-Benzyl-2-phenyl-2,3-dihydro-benzo[e][1,3,2]oxazaphosphinin-4-one 
• 198767-48-5 3-Benzyl-2-phenyl-2-thioxo-2,3-dihydro-2λ⁵-benzo[e][1,3,2]oxazaphosphinin-4-one 
• 1369423-64-2 11-benzyl-3-(tetrahydro-2H-pyran-2-yl)benzo[f]pyridazino[4,5-b][1,4]oxazepine-4,10(3H,11H)-dione 
• 1356540-93-6 2,2'-(2,2'-oxybis(ethane-2,1-diyl)-bis(oxy))bis(N-benzylbenzamide) 
• 1286252-33-2 2,2'-(2,2'-(ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))bis(oxy)bis(N-benzylbenzamide) 
• 67556-67-6 N-benzyl-2-hydroxybenzothioamide 
• 1414446-25-5 benzyl-N,N-bis[2-(2'-(benzylaminofomyl)phenoxy)ethyl]amine 
• 1332713-62-8 butyl-N,N-bis[((2'-benzylaminoformyl)phenoxyl)ethyl]amine 
• 1321192-19-1 10-benzyl-7-nitrodibenzo[b,f][1,4]oxazepin-11(10H)-one 
• 1095520-57-2 1,4-bis([(2'-benzylaminoformyl)phenoxyl]ethoxyl)benzene 
• 108678-94-0 diacetato-bis(N-benzylsalicylamide)copper(II) 
• 139554-11-3 N-Benzyl-2-hydroxy-N-(4-morpholin-4-yl-2,5-dioxo-1-phenyl-2,5-dihydro-1H-pyrrol-3-yl)-benzamide 
• 139554-14-6 N-Benzyl-2-hydroxy-N-(2-oxo-1-phenyl-2,4-dihydro-1H-pyrrolo[2,3-b]quinoxalin-3-yl)-benzamide 
• 139554-03-3 N-Benzyl-N-(2',5'-dioxo-1'-phenyl-2,3,4,5,2',5'-hexahydro-1'H-[1,3']bipyrrolyl-4'-yl)-2-hydroxy-benzamide 

Relevant articles and documents

Synthesis and luminescence properties of 2-(benzylcarbamoyl)phenyl derivatives and their europium complexes

Six novel 2-(benzylcarbamoyl)phenyl derivatives were synthesized and characterized by 1H-NMR, mass spectrometry, infrared spectra and elemental analysis. Their europium complexes were prepared and characterized by elemental analysis, EDTA titri

Graphene oxide: A convenient metal-free carbocatalyst for facilitating amidation of esters with amines

Herein, we report a graphene oxide (GO) catalyzed condensation of non-activated esters and amines, that can enable diverse amides to be synthesized from abundant ethyl esters forming only volatile alcohol as a by-product. GO accelerates ester to amide conversion in the absence of any additives, unlike other catalysts. A wide range of ester and amine substrates are screened to yield the respective amides in good to excellent yields. The improved catalytic activity can be ascribed to the oxygenated functionalities present on the graphene oxide surface which forms H-bonding with the reactants accelerating the reaction. Improved yields and a wide range of functional group tolerance are some of the important features of the developed protocol.

IDO inhibitors

Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.